Randomized Double Blind Placebo-controlled Clinical Safety, Tolerability and Pharmacokinetic/-Dynamic Study on the Effects of Escalating Single Intravenous Doses of EA-230 on the Innate Immune Response During Experimental Human Endotoxemia
Phase of Trial: Phase I
Latest Information Update: 28 Jun 2016
At a glance
- Drugs EA 230 (Primary)
- Indications Renal failure
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Exponential Biotherapies
- 22 Jun 2016 Status changed from active, no longer recruiting to completed.
- 11 Dec 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 28 Nov 2014 New trial record